Johnson & Johnson stock carries a USD 320 UBS price target

Published on 09/28/2026 at 13:07 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Johnson & Johnson stock was last at USD 271.22 on September 25, 2026, while UBS lifted its target from USD 280.00. Q2 revenue rose 6.6 percent.

Modern hospital operating room with robotic surgical arms positioned above a draped patient, surgeons in blue sterile gowns monitoring vital-sign and anatomy screens, bright overhead surgical lighting, stainless steel instrument trays in the foreground — Johnson und US4781601046 zeigen modernen Krankenhaus OP mit Robotik Chirurgie und medizinischen Bildschirmen, Illustration mit AI erstellt.

Johnson & Johnson stock (ISIN US4781601046) was last at USD 271.22 on the NYSE on September 25, 2026 at 4:00 p.m. ET, up 0.20 percent from the prior close. The central catalyst remains a September 2, 2026 UBS price-target increase to USD 320.00 from USD 280.00, reported by CNBC.

UBS raises the valuation bar

According to CNBC on September 2, 2026, UBS linked its more constructive view to expected top-line growth above the historical 4 percent to 6 percent compound annual growth rate and to a larger contribution from higher-margin products. The target implies USD 48.78 per share above the September 25 price, or 17.98 percent.

MarketBeat reported on September 2, 2026 that UBS retained a Buy rating while raising the target to USD 320.00. The same report cited talc litigation and insider selling as counter-factors that could pressure future earnings and valuation.

Revenue growth supports the case

Johnson & Johnson generated USD 25.31 billion in second-quarter 2026 revenue, an increase of 6.6 percent from the same quarter a year earlier, according to MarketBeat. Management set fiscal 2026 earnings-per-share guidance at USD 11.60-11.75, giving the valuation debate a current operating reference.

The growth mix matters because the company combines Innovative Medicine with MedTech. The September 2 analysis highlighted oncology, immunology and higher-margin products, while Johnson & Johnson's broad healthcare portfolio gives the stock a different earnings profile from a single-drug developer.

Stock remains below its yearly peak

At USD 271.22, the stock stood 3.50 percent below its 52-week high of USD 281.07 and 50.84 percent above its 52-week low of USD 179.80 on September 25, 2026. Trading volume was 4,059,419 shares and market capitalization was USD 653.6 billion.

The next quarterly report is scheduled for October 13, 2026, with third-quarter 2026 as the reporting period, according to TradingView. That update will test whether the 6.6 percent second-quarter revenue growth can support the higher valuation now reflected in the UBS target.